In:
Frontiers in Immunology, Frontiers Media SA, Vol. 12 ( 2022-1-10)
Abstract:
To explore the potential mechanism of cancer patients appearing more vulnerable to SARS-CoV-2 infection and poor COVID-19 outcomes, we conducted an integrative bioinformatics analysis for SARS-CoV-2-required genes and host genes and variants related to SARS-CoV-2 susceptibility and COVID-19 severity. BLCA, HNSC, KIRC, KIRP, LGG, PCPG, PRAD, TGCT, and THCA patients carrying rs10774671-A (OAS1) genotype may be more likely to have poor COVID-19 outcomes relative to those who carry rs10774671-G, because individuals carrying rs10774671-A will have lower expression of OAS1, which serves as a protective factor against SARS-CoV-2 processes and poor COVID-19 outcomes. SARS-CoV-2-required genes were correlated with TME, immune infiltration, overall survival, and anti-cancer drug sensitivity. CHOL patients may have a higher risk of SARS-CoV-2 infection than healthy subjects. SARS-CoV-2-induced ACE2 and NPC1 elevation may have a negative influence on the immune responses of LUSC and CD8+T infiltration of LUAD, and negatively affect the sensitivity of anti-lung cancer drugs. LUSC and LUAD patients may have a varying degree of adverse outcomes if they are infected with SARS-CoV-2. miR-760 may target and inhibit ACE2 expression. Cancer patients appearing vulnerable to SARS-CoV-2 infection and having poor COVID-19 outcomes may be partly due to host genetic factors and dysregulation of SARS-CoV-2-required genes. OAS1, ACE2, and miR-760 could serve as the treatment and intervention targets for SARS-CoV-2.
Type of Medium:
Online Resource
ISSN:
1664-3224
DOI:
10.3389/fimmu.2021.804387
DOI:
10.3389/fimmu.2021.804387.s001
DOI:
10.3389/fimmu.2021.804387.s002
DOI:
10.3389/fimmu.2021.804387.s003
DOI:
10.3389/fimmu.2021.804387.s004
DOI:
10.3389/fimmu.2021.804387.s005
DOI:
10.3389/fimmu.2021.804387.s006
DOI:
10.3389/fimmu.2021.804387.s007
DOI:
10.3389/fimmu.2021.804387.s008
DOI:
10.3389/fimmu.2021.804387.s009
DOI:
10.3389/fimmu.2021.804387.s010
DOI:
10.3389/fimmu.2021.804387.s011
DOI:
10.3389/fimmu.2021.804387.s012
DOI:
10.3389/fimmu.2021.804387.s013
DOI:
10.3389/fimmu.2021.804387.s014
Language:
Unknown
Publisher:
Frontiers Media SA
Publication Date:
2022
detail.hit.zdb_id:
2606827-8
Permalink